As Vertex Pharmaceuticals looks ahead to a launch this year of a cystic fibrosis drug that could treat 10 times as many patients as its current drug, it appears to be taking a lesson from the backlash in early 2014 against hepatitis C drug, Sovaldi.
On a conference call with analysts this week to discuss its fourth-quarter and full-year financial results, Vertex (Nasdaq: VRTX) Chief Commercial Officer Stuart Arbuckle outlined the company’s plans for lumacaftor, which is expected to be approved in the U.S. by July 5 and in Europe sometime toward the end of the year.
Help employers find you! Check out all the jobs and post your resume.
